Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

IO102-IO103 Plus Pembrolizumab Improves PFS in Treatment-Naive Advanced Melanoma

October 20th 2025

IO102-IO103 plus pembrolizumab was associated with a clinically relevant improvement in median progression-free survival.

FDA Accepts BLA Resubmission for RP1 Plus Nivolumab in Advanced Melanoma

October 20th 2025

Will the FDA approve a resubmitted biologics license application for RP1 plus nivolumab in advanced melanoma after progression on anti–PD-1 therapy?

Pembrolizumab/Lenvatinib Combo Is Active, Safe in Uveal Melanoma

October 19th 2025

Pembrolizumab plus lenvatinib was safe and active in HLA-A*02:01–negative and –positive uveal melanoma.

Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma

October 18th 2025

Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

Incidence of Second Primary Tumors Is Similar Between Adjuvant Cemiplimab and Placebo in High-Risk CSCC

October 18th 2025

Adjuvant cemiplimab and placebo were associated with similar rates of second primary tumors in high-risk CSCC.

Phase 2 BNT111/Cemiplimab Data Prove Positive in PD-(L)1-Relapsed/Refractory Melanoma

October 18th 2025

BNT111 plus cemiplimab achieved an 18.1% ORR in PD-(L)1–refractory melanoma, meeting its primary end point in the phase 2 BNT111-01 trial.

Adjuvant Cemiplimab Recommended for European Approval in CSCC

October 17th 2025

The EMA’s CHMP has recommended the approval of adjuvant cemiplimab in CSCC at high risk of recurrence after surgery and radiation

Dr Patel on the FDA Approval of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma

October 16th 2025

Vishal A. Patel, MD, discusses the FDA approval of adjuvant cemiplimab for CSCC at high risk of recurrence following surgery and radiation.

The OncFive: Top Oncology Articles for the Week of 10/5

October 11th 2025

The FDA approved adjuvant cemiplimab in cutaneous squamous cell carcinoma, issued a CRL to dasatinib in chronic myeloid leukemia, and more.

FDA Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell Carcinoma

October 8th 2025

The FDA approved cemiplimab-rwlc for the adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy

October 8th 2025

WTX-124 has received fast track designation from the FDA for locally advanced or metastatic cutaneous melanoma after standard-of-care immunotherapy.

Melanoma Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 8th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in melanoma.

The OncFive: Top Oncology Articles for the Week of 9/28

October 4th 2025

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

Q4 2025: 10 FDA Decisions to Watch in the Realm of Oncology

October 3rd 2025

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

Neoadjuvant Daromun Yields Improved Recurrence-Free Survival in Locally Advanced Melanoma

October 2nd 2025

Significantly longer recurrence-free survival has been demonstrated with neoadjuvant daromun vs surgery alone in patients with locally advanced melanoma.

Dr Rischin on the Safety of Adjuvant Cemiplimab in High-Risk CSCC

October 1st 2025

Danny Rischin, MD, discusses safety findings from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.

Dr Mehnert on Next Steps for the Evaluation of Quadruplet Therapy in Advanced Melanoma

September 26th 2025

Janice M. Mehnert, MD, discusses the ongoing investigation of sarilumab plus ipilimumab, nivolumab, and relatlimab in unresectable stage III/IV melanoma.

Dr Nathan on the Mechanism of Action of Roginolisib in Metastatic Uveal Melanoma

September 26th 2025

Paul Nathan, MBBS, PhD, MRCP, describes the mechanism of action of roginolisib and its ongoing evaluation in metastatic uveal melanoma.

Dr Rischin on the Efficacy of Adjuvant Cemiplimab in High-Risk CSCC

September 24th 2025

Danny Rischin, MD, discusses key DFS data from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.

Lifileucel Shows Durable 5-Year Benefit in Advanced Melanoma Resistant to Immune Checkpoint Inhibitors

September 24th 2025

Theresa Medina, MD, discusses 5-year C-144-01 results with lifileucel in advanced melanoma.